Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jun;67(6):1361–1367. doi: 10.1038/bjc.1993.252

CA 125 half-life in ovarian cancer: a multivariate survival analysis.

C A Yedema 1, P Kenemans 1, F Voorhorst 1, G Bon 1, C Schijf 1, L Beex 1, A Verstraeten 1, J Hilgers 1, J Vermorken 1
PMCID: PMC1968500  PMID: 8512822

Abstract

Serum CA 125 regression after cytoreductive surgery and during the first three courses of chemotherapy was studied in 60 ovarian cancer patients and compared to known prognostic factors. Various methods reported in the literature to calculate a CA 125 half-live value were compared. Using two exponential regression models (Van der Burg et al., 1988; Buller et al., 1991), mean half-lives in stage I-II patients after complete cytoreductive surgery were respectively 10.7 days (range: 5-23) and 9.8 days (range: 7-15). Within stage III-IV patients, a significant positive correlation was seen between survival and (a) stage III (P = 0.002), (b) residual tumour < or = 1 cm (P = 0.02), (c) CA 125 normalisation after three courses (P = 0.003) and (d) CA 125 half-life < or = 20 days (P = 0.02-0.004, depending on the method used for half-life calculation). The median survival times of patients with and without a CA 125 normalisation after three courses were 27 and 14 months respectively (P = 0.003). When using the model of Buller et al. patients with a CA 125 half-life < or = 20 days had a median survival of 28 months compared to a median survival of 19 months for patients with CA 125 half-lives > 20 days (P = 0.004). Half-life calculations only showed a significant correlation with survival, if pre-surgery CA 125 levels were used as a baseline. In a survival analysis using the Cox proportional hazards model, stage of disease was the most predictive variable for survival (P = 0.006). The only additional independent prognostic factor for survival was the CA 125 half-life calculated according to Buller [derived from the formula: CA 125 = exp. [i-s x (days after surgery)], in which i is the y-axis intercept and s is the slope of the CA 125 regression curve]. A CA 125 half-life < or = 20 days vs > 20 days calculated using this formula, provides an independent prognostic factor for survival in stage III-IV patients early in the course of therapy (P = 0.04).

Full text

PDF
1361

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  2. Buller R. E., Berman M. L., Bloss J. D., Manetta A., DiSaia P. J. CA 125 regression: a model for epithelial ovarian cancer response. Am J Obstet Gynecol. 1991 Aug;165(2):360–367. doi: 10.1016/0002-9378(91)90093-7. [DOI] [PubMed] [Google Scholar]
  3. Canney P. A., Moore M., Wilkinson P. M., James R. D. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984 Dec;50(6):765–769. doi: 10.1038/bjc.1984.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cruickshank D. J., Terry P. B., Fullerton W. T. CA125-response assessment in epithelial ovarian cancer. Int J Cancer. 1992 Apr 22;51(1):58–61. doi: 10.1002/ijc.2910510112. [DOI] [PubMed] [Google Scholar]
  5. Hawkins R. E., Roberts K., Wiltshaw E., Mundy J., Fryatt I. J., McCready V. R. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol. 1989 Dec;96(12):1395–1399. doi: 10.1111/j.1471-0528.1989.tb06301.x. [DOI] [PubMed] [Google Scholar]
  6. Hunter V. J., Daly L., Helms M., Soper J. T., Berchuck A., Clarke-Pearson D. L., Bast R. C., Jr The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1164–1167. doi: 10.1016/0002-9378(90)90680-6. [DOI] [PubMed] [Google Scholar]
  7. Högberg T., Kågedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand. 1990;69(5):423–429. doi: 10.3109/00016349009013306. [DOI] [PubMed] [Google Scholar]
  8. Jacobs I., Bast R. C., Jr The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989 Jan;4(1):1–12. doi: 10.1093/oxfordjournals.humrep.a136832. [DOI] [PubMed] [Google Scholar]
  9. Kottmeier H. L. Presentation of therapeutic results in carcinoma of the female pelvis: experience of the Annual Report on the Results of Treatment in Carcinoma of the Uterus, Vagina, and Ovary. Gynecol Oncol. 1976 Mar;4(1):13–19. doi: 10.1016/0090-8258(76)90002-0. [DOI] [PubMed] [Google Scholar]
  10. Lavin P. T., Knapp R. C., Malkasian G., Whitney C. W., Berek J. C., Bast R. C., Jr CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol. 1987 Feb;69(2):223–227. [PubMed] [Google Scholar]
  11. Mogensen O., Mogensen B., Jakobsen A. Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer. Gynecol Oncol. 1990 Apr;37(1):44–46. doi: 10.1016/0090-8258(90)90305-5. [DOI] [PubMed] [Google Scholar]
  12. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol. 1992 Mar;44(3):207–212. doi: 10.1016/0090-8258(92)90043-i. [DOI] [PubMed] [Google Scholar]
  13. Redman C. W., Blackledge G. R., Kelly K., Powell J., Buxton E. J., Luesley D. M. Early serum CA125 response and outcome in epithelial ovarian cancer. Eur J Cancer. 1990;26(5):593–596. doi: 10.1016/0277-5379(90)90085-8. [DOI] [PubMed] [Google Scholar]
  14. Rustin G. J., Gennings J. N., Nelstrop A. E., Covarrubias H., Lambert H. E., Bagshawe K. D. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol. 1989 Nov;7(11):1667–1671. doi: 10.1200/JCO.1989.7.11.1667. [DOI] [PubMed] [Google Scholar]
  15. Sevelda P., Schemper M., Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1989 Nov;161(5):1213–1216. doi: 10.1016/0002-9378(89)90668-6. [DOI] [PubMed] [Google Scholar]
  16. Willemse P. H., Aalders J. G., de Bruyn H. W., Mulder N. H., Sleijfer D. T., de Vries E. G. CA-125 in ovarian cancer: relation between half-life, doubling time and survival. Eur J Cancer. 1991;27(8):993–995. doi: 10.1016/0277-5379(91)90266-g. [DOI] [PubMed] [Google Scholar]
  17. Yedema K. A., Thomas C. M., Segers M. F., Doesburg W. H., Kenemans P. Comparison of five immunoassay procedures for the ovarian carcinoma-associated antigenic determinant CA 125 in serum. Eur J Obstet Gynecol Reprod Biol. 1992 Dec 28;47(3):245–252. doi: 10.1016/0028-2243(92)90159-v. [DOI] [PubMed] [Google Scholar]
  18. van der Burg M. E., Lammes F. B., van Putten W. L., Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol. 1988 Jul;30(3):307–312. doi: 10.1016/0090-8258(88)90244-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES